Table 4.
Concordance between TERTp and CTNNB1 mutations in HCC: clues from clinical studies.
| Region | Etiology (N) |
TERTp % Incidence (N) |
CTNNB1 % Incidence (N) |
Association | Ref. |
|---|---|---|---|---|---|
| France | 22% HBV+, 26% HCV+ (305) | 59% (179) | 33% (101) | Significant, p < 0.0001 | [5] |
| France | 20.7% HBV+, 26.5% HCV+ (801) | 58.1% (441) | 30.7% (229) | Significant, p = 0.0000001 | [103] |
| Southern Italy | 7.9% HBV+, 86.6% HCV+ (127) | 50.4% (64) | 26% (33) | Not significant, p = 0.4192 | [43] |
| USA and Japan | 25.6% HBV+, 42.6% HCV+ (469) | 54.1% (254) | 31.1% (146) | Significant, p < 0.0001 | [7] |
| Japan | NAFLD (11) |
82% (9) | 45% (5) | Not significant, p = 0.4545 | [54] |
| Taiwan | 63% HBV+, 40.2% HCV+ (195) | 29.2% (57) | 16.5% (31/188) | Not significant, p = 0.2055 | [34] |
| Korea | 74.3% HBV+, 5.7% HCV+; (105) | 39% (41) | 14.6% (15) | Not significant, p = 0.568 | [46] |
| China | 83% HBV+ (190) | 30% (57) | 24.3% (17/70) | Not significant, p = 0.535 | [53] |